RAPID MICRO BIOSYSTEMS, INC. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Numerator: | |||||||||||
| Net loss | $ | (46,889) | $ | (52,467) | |||||||
| Denominator: | |||||||||||
| Weighted average Class A common shares outstanding—basic and diluted | 38,266,176 | 37,612,962 | |||||||||
| Weighted average Class B common shares outstanding—basic and diluted | 5,309,529 | 5,411,077 | |||||||||
| Total shares for EPS—basic and diluted | 43,575,705 | 43,024,039 | |||||||||
| Net loss per share attributable to Class A common stockholders—basic and diluted | $ | (1.08) | $ | (1.22) | |||||||
| Net loss per share attributable to Class B common stockholders—basic and diluted | $ | (1.08) | $ | (1.22) | |||||||
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Options to purchase common stock | 6,296,505 | 6,530,511 | |||||||||
| Warrants to purchase common stock | 284,165 | 286,324 | |||||||||
| Unvested restricted common stock units | 1,941,688 | 1,681,760 | |||||||||
| Options to purchase common stock under ESPP | 102,509 | 224,510 | |||||||||
| 8,624,867 | 8,723,105 | ||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.